DOJ Cannabis Prohibition Policy: Federal Enforcement and Reform Timeline

Executive Summary

The U.S. Department of Justice acknowledged in July 2026 that cannabis prohibition interests no longer align with the American public's views, marking a historic shift in federal enforcement posture. This statement represents the most explicit federal admission to date that the Controlled Substances Act's Schedule I classification of cannabis has diverged from public consensus and state-level policy evolution. The DOJ's position comes amid ongoing rescheduling proceedings initiated by the Drug Enforcement Administration in 2024, following a recommendation from the Department of Health and Human Services to move cannabis from Schedule I to Schedule III under 21 U.S.C. § 812. The acknowledgment carries immediate implications for federal prosecutors, state-licensed operators, and the estimated 55 million American adults who use cannabis in states where it remains federally prohibited. As of mid-2026, 38 states have legalized medical cannabis and 24 have authorized adult-use programs, creating a $33 billion legal market operating in tension with federal law. The DOJ's statement does not constitute formal policy change but signals potential prosecutorial discretion shifts that could reshape enforcement priorities, banking access, and interstate commerce restrictions.

Why This Matters

The DOJ's acknowledgment affects every stakeholder in the $33 billion U.S. cannabis industry and the 400,000+ workers it employs. For state-licensed operators, the statement provides the strongest federal signal yet that enforcement priorities may continue shifting away from compliant businesses, though it offers no legal safe harbor from prosecution under 21 U.S.C. § 841. Multi-state operators face ongoing challenges with banking access, as financial institutions remain subject to federal money laundering statutes despite FinCEN guidance issued in 2014. The SAFE Banking Act has passed the House seven times since 2019 but has not cleared the Senate, leaving operators dependent on cash transactions and limited credit access. For patients, the misalignment between federal prohibition and state programs creates tangible barriers. Veterans receiving care through the Department of Veterans Affairs cannot receive cannabis recommendations from VA physicians, even in states with legal medical programs. Federal employees and contractors face termination for state-legal cannabis use due to the Drug-Free Workplace Act of 1988. Housing assistance recipients risk eviction under federal public housing rules that prohibit Schedule I substance use, regardless of state law. The economic stakes extend beyond direct industry participants. States collected $3.7 billion in cannabis tax revenue in 2025, funding education, infrastructure, and social equity programs. Federal prohibition under 26 U.S.C. § 280E prevents cannabis businesses from deducting ordinary business expenses, creating effective tax rates exceeding 70% and forcing operators to remit an estimated $1.8 billion annually in excess federal taxes. The DOJ's position may influence Congressional appetite for 280E reform and broader normalization measures.

Background and History

The Controlled Substances Act and Schedule I Classification

Cannabis prohibition became federal law on October 27, 1970, when President Richard Nixon signed the Controlled Substances Act into law as Title II of the Comprehensive Drug Abuse Prevention and Control Act. The CSA established five schedules for controlled substances, with Schedule I reserved for drugs deemed to have high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. Cannabis was placed in Schedule I alongside heroin and LSD, a classification that has remained unchanged for 56 years despite evolving scientific understanding and state-level policy reforms. The CSA's passage followed decades of cannabis prohibition that began with state-level laws in the 1910s and 1920s, culminating in the federal Marihuana Tax Act of 1937. The 1970 law replaced the tax-based prohibition scheme with direct criminal penalties under the Commerce Clause, establishing federal jurisdiction over cannabis regardless of whether it crossed state lines. Possession became punishable by up to one year imprisonment and a $5,000 fine under 21 U.S.C. § 844, while manufacturing and distribution carried penalties up to life imprisonment under 21 U.S.C. § 841.

Early Challenges and the Shafer Commission

Within two years of the CSA's enactment, a presidential commission recommended decriminalizing personal cannabis possession, advice that went unheeded for five decades. The National Commission on Marihuana and Drug Abuse, chaired by former Pennsylvania Governor Raymond Shafer, delivered its report "Marihuana: A Signal of Misunderstanding" to Congress in March 1972. The commission found that cannabis posed minimal public health risk compared to alcohol and recommended eliminating criminal penalties for possession of small amounts for personal use. President Nixon rejected the findings, and federal prohibition intensified throughout the 1970s and 1980s. The Reagan administration's "War on Drugs" expanded federal enforcement resources and penalties. The Anti-Drug Abuse Act of 1986 established mandatory minimum sentences for drug offenses, and annual federal cannabis arrests grew from approximately 400,000 in 1980 to more than 700,000 by 2000. The vast majority of arrests were for simple possession rather than trafficking.

State-Level Medical Cannabis Programs Begin

California voters approved Proposition 215 on November 5, 1996, creating the first state-legal medical cannabis program in direct conflict with federal Schedule I status. The Compassionate Use Act allowed patients with physician recommendations to possess and cultivate cannabis for medical purposes, establishing a state-federal legal conflict that persists today. Alaska, Oregon, and Washington followed with medical programs in 1998, and Maine voters approved medical access in 1999. The federal response was swift. The Department of Justice under President Bill Clinton announced that physicians recommending cannabis could face federal prosecution and loss of DEA prescribing authority. The Ninth Circuit Court of Appeals ruled in Conant v. Walters (2003) that the First Amendment protected physician-patient discussions about cannabis, but federal enforcement against dispensaries and cultivators continued. The Supreme Court ruled in United States v. Oakland Cannabis Buyers' Cooperative (2001) that medical necessity was not a defense to federal cannabis charges, and in Gonzales v. Raich (2005) that Congress could prohibit intrastate cannabis cultivation under the Commerce Clause even when authorized by state law.

The Obama-Era Enforcement Shift

On October 19, 2009, Deputy Attorney General David Ogden issued the first DOJ memorandum directing federal prosecutors not to focus resources on individuals in clear compliance with state medical cannabis laws. The "Ogden Memo" represented a significant prosecutorial discretion shift, though it explicitly stated that federal law remained unchanged and prosecution remained possible. The memo applied only to seriously ill individuals and their caregivers, not commercial operations. As state medical programs expanded and commercial dispensaries proliferated, the DOJ issued clarifying guidance. Deputy Attorney General James Cole released a memorandum on August 29, 2013 (the "Cole Memo") establishing eight enforcement priorities: preventing distribution to minors, preventing revenue to criminal enterprises, preventing diversion to non-legal states, preventing state-authorized activity from being a cover for trafficking, preventing violence and firearms use, preventing drugged driving, preventing cultivation on public lands, and preventing possession on federal property. State-licensed operators in compliance with robust regulatory systems were deprioritized for federal enforcement. The Cole Memo governed federal enforcement for four years and enabled significant industry growth. By 2017, 29 states had medical programs and eight had legalized adult use. The legal market reached $10 billion in annual sales.

The Sessions Rescission and Return to Uncertainty

Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, returning enforcement decisions to individual U.S. Attorneys and creating renewed uncertainty for state-licensed operators. The "Sessions Memo" stated that federal prosecutors should follow established principles governing all federal prosecutions, weighing factors including seriousness of the crime and deterrent effect. Sessions called cannabis a "dangerous drug" and stated that its use was "only slightly less awful" than heroin. Despite the rescission, large-scale federal enforcement against state-compliant operators did not materialize. Congressional appropriations riders prohibited the DOJ from using funds to prevent states from implementing medical cannabis laws, providing limited protection. The Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer) has been renewed in every appropriations bill since 2014, though it applies only to medical programs and does not protect adult-use markets.

The Biden Administration and Rescheduling

President Joe Biden directed HHS and DOJ to review cannabis scheduling on October 6, 2022, initiating the most significant federal reconsideration of cannabis policy since 1970. The directive followed decades of advocacy and mounting evidence that Schedule I criteria did not reflect scientific consensus on cannabis. HHS completed its review in August 2023 and recommended rescheduling cannabis to Schedule III, finding that it has currently accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking on May 16, 2024, proposing to reschedule cannabis to Schedule III under 21 U.S.C. § 811(a). The NPRM initiated a public comment period that drew more than 45,000 submissions, and the DEA scheduled administrative law judge hearings for late 2024 and early 2025. As of July 2026, the rescheduling process remains pending, with no final rule published.

Key Players

Department of Justice

The DOJ holds primary federal enforcement authority over cannabis through the DEA and U.S. Attorneys' offices in 94 federal districts. The department's position has oscillated between aggressive enforcement and prosecutorial restraint depending on administration priorities. Attorney General Merrick Garland has maintained a lower-profile approach than his predecessors, neither issuing broad enforcement guidance nor publicly advocating for prohibition. The July 2026 statement acknowledging misalignment with public interests represents the most explicit DOJ position on cannabis policy under the Biden administration. The DEA, operating within DOJ, controls scheduling decisions under 21 U.S.C. § 811 and maintains final authority over rescheduling proceedings. DEA Administrator Anne Milgram has overseen the ongoing Schedule III rescheduling process while maintaining that cannabis remains a Schedule I controlled substance subject to enforcement until any rule change takes effect.

Department of Health and Human Services

HHS provided the scientific and medical analysis underlying the 2023 recommendation to reschedule cannabis to Schedule III. The recommendation followed a comprehensive review by the Food and Drug Administration, which found that cannabis has currently accepted medical use in the United States, has lower abuse potential than Schedule I or II substances, and presents moderate to low risk of physical dependence. The HHS recommendation is binding on DEA regarding scientific and medical matters under 21 U.S.C. § 811(b), though DEA retains authority over final scheduling decisions.

State Governments and Regulatory Agencies

Thirty-eight states have implemented medical cannabis programs and 24 have legalized adult use, creating a patchwork of regulatory frameworks operating in tension with federal prohibition. California operates the largest legal market, with the Department of Cannabis Control overseeing approximately 10,000 licensed businesses generating $5.3 billion in annual sales. New York launched adult-use sales in December 2022 under the Office of Cannabis Management, issuing conditional licenses prioritizing social equity applicants. Ohio voters approved adult-use legalization in November 2023, with sales beginning in August 2024 under the Division of Cannabis Control. State programs vary significantly in structure, with some states like Washington operating retailer-only models prohibiting vertical integration, while others like Illinois allow multi-state operators to hold cultivation, processing, and retail licenses. Possession limits range from one ounce in Massachusetts to three ounces in Maine for adult use, and from 2.5 ounces in Illinois to 24 ounces in Oregon for medical patients.

Multi-State Operators

Publicly traded MSOs including Curaleaf, Green Thumb Industries, Trulieve, and Verano operate in multiple state markets while navigating federal prohibition constraints. These operators face unique challenges including inability to list on major U.S. stock exchanges due to federal illegality, forcing trading on Canadian exchanges or over-the-counter markets. Curaleaf operates 151 dispensaries across 18 states and reported $1.3 billion in revenue for 2025. Trulieve dominates the Florida medical market with 191 retail locations and reported $1.1 billion in 2025 revenue. MSOs have advocated for federal reform including SAFE Banking access, 280E repeal, and interstate commerce authorization. The industry formed the Cannabis Trade Federation and U.S. Cannabis Council to coordinate lobbying efforts, spending approximately $4.8 million on federal lobbying in 2025.

Reform Advocacy Organizations

NORML, the Drug Policy Alliance, and the Marijuana Policy Project have led advocacy for cannabis policy reform for decades. NORML, founded in 1970, focuses on decriminalization and legalization advocacy at state and federal levels. The Drug Policy Alliance emphasizes criminal justice reform and harm reduction approaches to drug policy. The Marijuana Policy Project has coordinated ballot initiative campaigns in multiple states and lobbies for federal reform legislation. These organizations have documented racial disparities in cannabis enforcement, noting that Black Americans are arrested for cannabis offenses at 3.64 times the rate of white Americans despite similar usage rates, according to ACLU data. Advocacy groups have pushed for social equity provisions in state legalization programs and expungement of prior cannabis convictions.

Prohibition Advocacy Groups

Smart Approaches to Marijuana and the Community Anti-Drug Coalitions of America oppose legalization and advocate for maintaining criminal penalties. SAM, founded by former Representative Patrick Kennedy and Kevin Sabet, argues that cannabis legalization increases youth use, impaired driving, and mental health harms. The organization has opposed state legalization ballot measures and federal reform legislation. CADCA coordinates local anti-drug coalitions and has testified before Congress against rescheduling and legalization measures. Law enforcement organizations including the National Sheriffs' Association have historically opposed legalization, though some police chiefs' organizations have supported decriminalization as a resource allocation matter.

Legal and Regulatory Framework

Federal Statutory Framework

Cannabis remains prohibited under 21 U.S.C. § 841, which makes it unlawful to manufacture, distribute, or possess with intent to distribute a controlled substance. Penalties scale with quantity, with 100 kilograms or more carrying a mandatory minimum sentence of five years and maximum of 40 years for a first offense. Simple possession under 21 U.S.C. § 844 carries up to one year imprisonment and a minimum $1,000 fine for a first offense. The Controlled Substances Act establishes criteria for Schedule I classification in 21 U.S.C. § 812(b)(1): high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Schedule III substances under § 812(b)(3) have currently accepted medical use, lower abuse potential than Schedule I or II, and moderate to low potential for physical dependence. Federal law preempts conflicting state law under the Supremacy Clause of Article VI of the Constitution. However, states are not required to enforce federal law, and federal resources are insufficient to enforce prohibition without state cooperation. This creates a practical federalism where state-legal markets operate despite ongoing federal prohibition.

Tax Code Section 280E

26 U.S.C. § 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses for federal tax purposes. The provision was enacted in 1982 following a Tax Court decision allowing a cocaine trafficker to deduct business expenses. Cannabis businesses can deduct cost of goods sold but cannot deduct rent, salaries, marketing, or other operating expenses, creating effective tax rates of 70% or higher. The IRS has aggressively audited cannabis businesses and assessed additional taxes based on 280E, generating an estimated $1.8 billion annually in excess federal tax revenue. If cannabis is rescheduled to Schedule III, 280E would no longer apply, providing significant tax relief to state-licensed operators. Industry analysts estimate that 280E repeal would increase cannabis business profitability by 20-30% and enable price reductions that could reduce illicit market competition.

Banking and Financial Services Restrictions

Federal money laundering statutes including 18 U.S.C. § 1956 and § 1957 create criminal liability for financial institutions handling proceeds of cannabis sales, even when state-legal. The Bank Secrecy Act requires financial institutions to file Suspicious Activity Reports for transactions involving illegal activity. FinCEN issued guidance in 2014 stating that financial institutions could serve cannabis businesses while managing risk through enhanced due diligence, but most banks have declined to serve the industry due to ongoing federal prohibition. Approximately 800 financial institutions served cannabis businesses as of 2025, according to FinCEN data, but most operators remain unbanked or underbanked. The SAFE Banking Act would create a safe harbor for financial institutions serving state-compliant cannabis businesses, but has not become law despite passing the House seven times since 2019.

Federal Property and Employment Restrictions

Cannabis possession and use remain prohibited on all federal property under 21 U.S.C. § 844a, including national parks, military bases, and federal buildings. Federal employees are subject to drug testing under the Drug-Free Workplace Act of 1988 and Executive Order 12564, with positive cannabis tests resulting in termination regardless of state law. Federal contractors are similarly restricted. The Department of Transportation prohibits cannabis use by safety-sensitive transportation workers including commercial drivers, pilots, and railroad employees under 49 C.F.R. Part 40. Veterans receiving care through the VA cannot receive cannabis recommendations from VA physicians under federal law, though the VA updated its policy in 2021 to clarify that veterans will not be denied services for cannabis use alone.

State-by-State Breakdown

California

California operates the nation's largest legal cannabis market, with adult-use sales authorized since January 1, 2018, under Proposition 64 (the Adult Use of Marijuana Act). The state allows possession of up to one ounce of flower and eight grams of concentrate for adults 21 and older. Home cultivation of up to six plants per residence is permitted. The Department of Cannabis Control oversees licensing for cultivation, manufacturing, distribution, testing, and retail. The state collected $1.1 billion in cannabis tax revenue in 2025, though tax rates have been reduced to compete with the illicit market. California reduced the cultivation tax to zero in 2022 and lowered the excise tax from 15% to 13% in 2025.

Colorado

Colorado became the first state to implement adult-use sales on January 1, 2014, following voter approval of Amendment 64 in November 2012. Adults 21 and older may possess up to one ounce and cultivate up to six plants, with three flowering at a time. The Marijuana Enforcement Division within the Department of Revenue regulates the industry. Colorado collected $423 million in cannabis tax revenue in 2025, funding school construction, drug treatment programs, and law enforcement. The state has implemented strict packaging and testing requirements and prohibits products appealing to children.

New York

New York launched adult-use sales in December 2022 under the Marijuana Regulation and Taxation Act, signed by Governor Kathy Hochul in March 2021. Adults 21 and older may possess up to three ounces of flower and 24 grams of concentrate. Home cultivation remains prohibited pending regulatory development. The Office of Cannabis Management prioritized Conditional Adult-Use Retail Dispensary licenses for justice-involved individuals and those from communities disproportionately impacted by prohibition. The state aims to allocate 50% of licenses to social equity applicants. New York collected $156 million in cannabis tax revenue in 2025, its first full year of legal sales.

Florida

Florida operates a medical-only program authorized by constitutional amendment in 2016, with no adult-use legalization to date. Qualified patients with physician certifications may possess up to 2.5 ounces of flower in a 35-day period. The state has issued 22 Medical Marijuana Treatment Center licenses, with operators including Trulieve, Curaleaf, and Verano operating more than 600 dispensaries statewide. Florida's program serves approximately 850,000 registered patients, one of the nation's largest medical markets. A ballot initiative to legalize adult use failed to achieve the required 60% threshold in November 2024, receiving 58% support.

Texas

Texas maintains one of the nation's most restrictive medical cannabis programs, limited to low-THC products for a narrow list of qualifying conditions. The Compassionate Use Program allows patients with epilepsy, seizure disorders, multiple sclerosis, spasticity, ALS, autism, cancer, and PTSD to access products containing no more than 1% THC by weight. Possession of any amount of cannabis flower remains a criminal offense, with possession of two ounces or less classified as a Class B misdemeanor punishable by up to 180 days in jail and a $2,000 fine. Several Texas cities including Austin, Dallas, and Houston have adopted local decriminalization policies deprioritizing enforcement of low-level possession offenses.

Ohio

Ohio voters approved adult-use legalization through Issue 2 on November 7, 2023, with sales beginning on August 6, 2024. Adults 21 and older may possess up to 2.5 ounces and cultivate up to six plants per individual or 12 per residence. The Division of Cannabis Control within the Department of Commerce regulates the industry. Ohio's medical program, operational since 2019, serves approximately 130,000 registered patients. The state collected $27 million in adult-use tax revenue in the first four months of sales.

Prohibition States

Twelve states maintain complete prohibition of cannabis with no medical or adult-use programs: Idaho, Kansas, Nebraska, South Carolina, Tennessee, Wisconsin, Wyoming, Indiana, Iowa, Kentucky, Georgia, and North Carolina. These states impose criminal penalties for any possession, with severity varying by state. Idaho classifies any amount of possession as a misdemeanor punishable by up to one year in jail and a $1,000 fine, with no decriminalization or medical exception. Kansas similarly prohibits all possession, with first-time possession of any amount classified as a Class A misdemeanor carrying up to one year imprisonment and a $2,500 fine. Several prohibition states have considered medical cannabis legislation in recent years. Kentucky enacted a medical program in 2023 with sales expected to begin in 2025. North Carolina's House approved medical legalization in 2023, but the Senate did not advance the measure.

Market and Business Implications

Multi-State Operator Impact

The DOJ's acknowledgment that prohibition interests diverge from public consensus could accelerate institutional investment in cannabis MSOs and improve access to capital markets. Publicly traded cannabis companies have faced significant capital constraints due to federal prohibition, with major institutional investors including pension funds and mutual funds largely prohibited from cannabis holdings. Canadian cannabis companies including Canopy Growth and Tilray have accessed U.S. markets through complex holding structures, but U.S. operators remain unable to list on the New York Stock Exchange or Nasdaq. If the DOJ position translates into formal policy changes or Congressional action, MSOs could gain access to traditional banking services, institutional capital, and major stock exchanges. Analysts estimate that SAFE Banking passage alone would reduce cannabis business capital costs by 300-500 basis points and enable industry consolidation through debt-financed acquisitions. Curaleaf, Green Thumb Industries, Trulieve, and Verano have a combined market capitalization of approximately $8 billion as of July 2026, down from peaks exceeding $25 billion in early 2021.

Wholesale Pricing and Supply Dynamics

Federal prohibition has prevented interstate commerce in cannabis, creating isolated state markets with significant price disparities and supply imbalances. Wholesale cannabis flower prices in Oregon averaged $850 per pound in July 2026, while prices in Illinois averaged $2,400 per pound for comparable quality. The price differential reflects supply constraints in limited-license states like Illinois, where the state caps cultivation licenses, versus mature markets like Oregon where unlimited licensing created oversupply. Interstate commerce authorization would enable efficient resource allocation, with low-cost producers in agricultural states like California and Oregon supplying high-demand markets in the Northeast and Midwest. Industry analysts estimate that interstate commerce would reduce wholesale prices by 30-50% in constrained markets while providing price support in oversupplied markets. However, interstate commerce would require federal legalization or explicit Congressional authorization, as the Controlled Substances Act prohibits interstate trafficking in Schedule I substances.

280E Tax Implications

Cannabis rescheduling to Schedule III would eliminate 280E tax burdens, improving operator profitability by an estimated 20-30% and enabling price reductions to compete with illicit markets. State-licensed cannabis businesses currently pay effective federal tax rates of 70% or higher due to inability to deduct ordinary business expenses. A typical dispensary with $5 million in revenue, $3 million in cost of goods sold, and $1.5 million in operating expenses would owe federal tax of approximately $450,000 under normal tax rules (21% corporate rate on $500,000 taxable income after deductions). Under 280E, the same business owes federal tax of approximately $840,000 (21% on $4 million taxable income with no operating expense deductions). 280E repeal would free significant capital for business reinvestment, price reductions, and wage increases. Industry groups estimate that cannabis businesses could reduce retail prices by 10-15% while maintaining current margins if 280E were eliminated. Lower prices would reduce illicit market competitiveness, which remains significant in states like California where unlicensed operators undercut legal retailers by 30-40% on price.

Investment and Capital Formation

Federal policy uncertainty has constrained cannabis industry access to growth capital, with total industry investment declining from $3.8 billion in 2021 to $1.2 billion in 2025. Venture capital and private equity firms have reduced cannabis exposure due to federal prohibition risks and poor returns in early investments. Many cannabis companies that went public through reverse mergers or Canadian listings in 2018-2020 have seen share prices decline 70-90% from peaks. The DOJ's acknowledgment of misalignment with public interests could signal reduced federal enforcement risk and encourage renewed investment. However, institutional investors are likely to await concrete policy changes rather than rhetorical shifts. SAFE Banking passage, rescheduling finalization, or comprehensive legalization would provide clearer investment frameworks.

What Experts Say

Cannabis policy researchers and legal scholars have documented the growing tension between federal prohibition and state-level legalization for more than a decade. Robert Mikos, a professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," has written extensively on federalism challenges created by conflicting state and federal cannabis laws. According to Mikos's published research, federal prohibition has become increasingly difficult to enforce as state-legal markets have proliferated, creating a practical form of nullification where federal law remains on the books but is not enforced against state-compliant actors. The RAND Corporation published research in 2023 examining the public health and safety impacts of state cannabis legalization. According to the RAND analysis, states with legal cannabis markets have not experienced the dramatic increases in youth use or impaired driving that prohibition advocates predicted, though the research noted methodological challenges in isolating cannabis policy effects from broader social trends. The American Civil Liberties Union has documented racial disparities in cannabis enforcement, publishing data showing that Black Americans are arrested for cannabis offenses at 3.64 times the rate of white Americans despite similar usage rates. According to ACLU analysis, cannabis prohibition has been a primary driver of mass incarceration and racial disparities in the criminal justice system. The National Academy of Sciences, Engineering, and Medicine published a comprehensive review of cannabis health effects in 2017, finding conclusive or substantial evidence that cannabis is effective for chronic pain, chemotherapy-induced nausea, and multiple sclerosis spasticity. The review found moderate evidence of cannabis efficacy for sleep disorders and limited evidence for various other conditions. The NAS report noted that Schedule I classification has hindered clinical research on cannabis therapeutic potential.

What's Next

Rescheduling Timeline and Process

The DEA's Schedule III rescheduling process remains pending as of July 2026, with administrative law judge hearings completed in early 2025 and a final rule expected by late 2026 or early 2027. The ALJ must issue recommended findings to the DEA Administrator, who will make a final scheduling determination. The process is governed by the Administrative Procedure Act, and any final rule will be subject to judicial review. Industry observers expect legal challenges from both prohibition advocates arguing that cannabis does not meet Schedule III criteria and legalization advocates arguing that cannabis should be descheduled entirely. If rescheduling to Schedule III is finalized, cannabis would remain a controlled substance subject to FDA regulation and DEA manufacturing quotas, but would no longer be subject to 280E tax penalties. Medical cannabis would require FDA approval for interstate commerce, though state-licensed programs could continue operating under state law. Rescheduling would not legalize adult-use cannabis or authorize interstate commerce without additional Congressional action.

Congressional Legislation Prospects

Multiple cannabis reform bills are pending in the 119th Congress, including the SAFE Banking Act, the Cannabis Administration and Opportunity Act, and the STATES Act. The SAFE Banking Act would create a safe harbor for financial institutions serving state-compliant cannabis businesses and has the strongest bipartisan support, having passed the House seven times since 2019. Senate Banking Committee Chair Sherrod Brown has expressed support for SAFE Banking but has sought to pair it with criminal justice reform provisions, complicating passage. The Cannabis Administration and Opportunity Act, sponsored by Senate Majority Leader Chuck Schumer, would deschedule cannabis entirely and establish a federal regulatory framework with excise taxes funding social equity programs and expungement. The bill has not advanced beyond committee consideration and faces opposition from Republicans and some moderate Democrats. The STATES Act would amend the Controlled Substances Act to exempt state-compliant cannabis activity from federal prohibition, creating a federalism approach similar to alcohol regulation. The bill has bipartisan sponsorship but has not received committee votes in recent Congresses. Congressional action on cannabis reform faces uncertain prospects in a divided political environment. Some observers expect that rescheduling completion could reduce pressure for comprehensive legislation, while others argue that rescheduling's limitations will increase demand for full legalization.

State Ballot Initiatives and Legislative Action

Cannabis legalization ballot initiatives are expected in Florida, Arkansas, and South Dakota in November 2026, with legislative campaigns underway in Pennsylvania, Minnesota, and Wisconsin. Florida voters will consider a constitutional amendment to legalize adult use after a similar measure fell just short of the required 60% threshold in 2024. Polling shows 64% support for the 2026 measure. Arkansas voters approved medical cannabis in 2016 and will consider adult-use legalization for the third time after measures failed in 2022 and 2024. South Dakota voters approved legalization in 2020, but the measure was invalidated by the state Supreme Court on procedural grounds; a new initiative has qualified for the 2026 ballot. Pennsylvania Governor Josh Shapiro has expressed support for adult-use legalization and has urged the legislature to pass a regulatory framework. The Pennsylvania House has advanced legalization bills in previous sessions, but the Republican-controlled Senate has not taken up the measures. Minnesota legalized adult use through legislation in 2023, with sales expected to begin in 2025. Wisconsin's Democratic governor has proposed legalization, but the Republican legislature has not advanced reform measures.

Federal Enforcement Scenarios

The DOJ's acknowledgment of misalignment with public interests could presage updated prosecutorial guidance similar to the Obama-era Cole Memo, or could remain rhetorical without policy implementation. If the department issues formal guidance deprioritizing enforcement against state-compliant operators, it would provide greater certainty for businesses and investors, though it would not create legal safe harbor from prosecution. Any guidance could be rescinded by a future administration, as occurred when Attorney General Sessions rescinded the Cole Memo in 2018. Alternatively, the DOJ could maintain current enforcement posture without issuing formal guidance, relying on resource constraints and prosecutorial discretion to avoid large-scale enforcement against state-compliant businesses. This approach would preserve maximum flexibility but would not provide industry certainty. A change in presidential administration in 2029 could significantly alter federal enforcement priorities. Republican candidates have expressed varying positions on cannabis policy, from continued prohibition to state-rights federalism approaches. Democratic candidates have generally supported legalization or rescheduling.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 2024) - https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS Recommendation to Reschedule Cannabis (August 2023) -